Rastetter William H insider trades
Rastetter William H has filed 32 Form 4s with the SEC that we hold, for Neurocrine Biosciences INC (NBIX) (Director), RGLS (Director), Dare Bioscience, Inc. (DARE) (Director) and Fate Therapeutics INC (FATE) (Director). Across all of them we count 0 purchases worth $0 and 8 sales worth $11.8M reported on Form 4. In the last 12 months: 0 purchases ($0) and 1 sale ($2.7M). The largest single trade was a sale of 30,000 shares of Neurocrine Biosciences INC worth $3.3M, dated 2025-05-05. The first filing on our record is dated 2022-04-05 and the latest 2026-07-02.
Neurocrine Biosciences INC (NBIX)
| Trade date | Code | Shares | Value as filed | Filed |
|---|---|---|---|---|
| 2022-04-01 | S, sale reported on Form 4 | 10,728 | $1.0M | 2022-04-05 |
| 2023-04-19 | S, sale reported on Form 4 | 903 | $94.8K | 2023-04-21 |
| 2023-04-21 | S, sale reported on Form 4 | 6,034 | $633.8K | 2023-04-21 |
| 2023-05-01 | S, sale reported on Form 4 | 4,300 | $436.1K | 2023-05-03 |
| 2024-01-02 | S, sale reported on Form 4 | 11,044 | $1.5M | 2024-01-04 |
| 2024-08-15 | S, sale reported on Form 4 | 14,250 | $2.1M | 2024-08-16 |
| 2025-05-05 | S, sale reported on Form 4 | 30,000 | $3.3M | 2025-05-07 |
| 2025-11-05 | S, sale reported on Form 4 | 18,000 | $2.7M | 2025-11-06 |
RGLS
No purchase or sale of common stock reported here; these filings cover grants, option exercises or other codes.
Dare Bioscience, Inc. (DARE)
No purchase or sale of common stock reported here; these filings cover grants, option exercises or other codes.
Fate Therapeutics INC (FATE)
No purchase or sale of common stock reported here; these filings cover grants, option exercises or other codes.
Counted from the Form 4 filings this reporting owner (SEC CIK 1205903) filed on EDGAR. Values are the transaction values as filed. See every filing on EDGAR, or browse insider buying and today's insider purchases.
Source: U.S. Securities and Exchange Commission (EDGAR) and other official
government data · Updated 2026-10-12 ·
For informational purposes only, not investment advice.
Privacy · Terms